Department of Dermatology, University Hospital Zurich, Switzerland.
J Dtsch Dermatol Ges. 2012 Jan;10(1):12-22; quiz 23. doi: 10.1111/j.1610-0387.2011.07852.x.
Cutaneous B-cell lymphomas (CBCL) are the second most common form of primary cutaneous lymphomas. The cutaneous follicle center lymphoma and the cutaneous marginal zone lymphoma (extranodal MALT type lymphoma) account for the vast majority of CBCL and manifest with nodules. These two lymphoma entities have an indolent, slowly progressive course and an excellent prognosis despite a high rate of recurrences. In contrast, cutaneous diffuse large B-cell lymphoma, leg type, and other rare forms of CBCL display an impaired prognosis and therefore require to be treated with multiagent chemotherapy and anti-CD20 monoclonal antibodies in most cases. Clinico-pathologic correlation, histology with immunohistochemical profile and genotyping as well as staging examinations are crucial diagnostic elements in the work-up of CBCL.
皮肤 B 细胞淋巴瘤(CBCL)是原发性皮肤淋巴瘤的第二大常见类型。皮肤滤泡中心淋巴瘤和皮肤边缘区淋巴瘤(结外黏膜相关淋巴组织型淋巴瘤)占 CBCL 的绝大多数,表现为结节。尽管复发率很高,但这两种淋巴瘤实体具有惰性、缓慢进展的过程和极好的预后。相比之下,皮肤弥漫性大 B 细胞淋巴瘤,腿型,和其他罕见形式的 CBCL 显示预后不良,因此大多数情况下需要联合化疗和抗 CD20 单克隆抗体治疗。临床病理相关性、组织学免疫组化表型和基因分型以及分期检查是 CBCL 诊断的关键要素。